Navigation Links
Neuralstem updates ALS clinical trial progress
Date:10/19/2010

ROCKVILLE, Maryland, October 18, 2010 Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first six non-ambulatory patients, the trial's Safety Monitoring Board has unanimously approved moving to the next group of ALS patients, all of whom will be ambulatory.

"We are pleased with the progress of the trial to date, and look forward to moving directly into more recently-diagnosed patients," commented Dr. Eva Feldman, PhD, MD, Principal Investigator of the trial and a consultant to Neuralstem. Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System.

"We are encouraged by the Board's approval to advance the trial to patients who have an earlier stage of the disease," said Neuralstem's CEO and president, Richard Garr. "While the primary endpoint of the trial is safety, we also hope to see some secondary endpoints showing efficacy. We are grateful to the patients, and their families, for participating in this trial."

The first six patients treated in the trial were non-ambulatory. Of these, the first three received five injections each, unilaterally, in the lumbar region of the spinal cord. The next three received ten injections each, bilaterally in the lumbar region. All of the remaining patients in the trial will be ambulatory, and therefore represent earlier stages of disease progression. Of the ambulatory group, the first three patients will receive five injections each, unilaterally, in the lumbar region. The next three will receive ten injections each, bilaterally, in the lumbar region. After the required FDA approval, the final six patients in the trial will receive injections in the cervical region, representing both a progression of treatment up the spinal cord, as well as into more recently-diagnosed patients.


'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Related medicine news :

1. Neuralstem chief scientific officer to take part in World Stem Cell Summit plenary session
2. Neuralstem stem cells survive and differentiate into neurons in rats with stroke
3. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
4. Neuralstem updates clinical trial progress
5. New "howsthepatient" iPhone App Provides a Simple, Seamless Way to Send Health Updates to Friends and Family
6. FDA Updates Import Alert 71-04 for Salmonella Contaminated Animal Feeds: Many Non-U.S. Firms Affected According to FDAImports.com, LLC
7. Clone Systems, Inc. Updates PCI Solutions for Level 1 & 2 Merchants
8. American Traveler Offers New Healthcare Jobs Hourly, Updates Via Job RSS & Twitter
9. Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates
10. Sunquest Announces Major Software Updates and Enhancements
11. New clinical trial explores role of vitamin D in preventing esophageal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Children ... to more adverse experiences than children in the general population. That’s because foster ... neglect or other family challenges. While no fault of their own, youth who ...
(Date:4/28/2017)... ... ... People are starting to accept that hearing aids can be helpful and ... it had when great-grandpa wore his hearing aids years ago,” said Dr. Maura Marks, ... American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing aid on ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... Manager for the North East region. Côté has 20+ years of experience within ... to Phytomer, Côté worked with an array of high-end cosmetic brands, retail brands ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Rob Lowe ... and now he has leant his presence to an educational purpose as the host ... one important one being cancer. In a recent episode, the series focuses on thyroid ...
(Date:4/27/2017)... ... April 27, 2017 , ... The Incentive Research Foundation is ... Nudge Guide," a groundbreaking analysis of how behavioral economics can be applied to ... to IRR programs, the report highlights proven behavioral economics approaches and the powerful ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... Research and Markets has announced ... Market Prospects: Addressing Production Complexities Through Risk Management and ... ... Pipeline and Market Prospects: Overcoming Production Complexities Through Risk ... of the current trends in the global biosimilars market, ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology: